Opin vísindi

What does it cost to redispense unused medications in the pharmacy? A micro-costing study

Skoða venjulega færslu

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Bekker, Charlotte L.
dc.contributor.author Gardarsdottir, Helga
dc.contributor.author Egberts, Antoine C. G.
dc.contributor.author Molenaar, Hendrik A.
dc.contributor.author Bouvy, Marcel L.
dc.contributor.author van den Bemt, Bart J. F.
dc.contributor.author Hövels, Anke M.
dc.date.accessioned 2020-04-30T14:04:56Z
dc.date.available 2020-04-30T14:04:56Z
dc.date.issued 2019-04-24
dc.identifier.citation Bekker, C.L., Gardarsdottir, H., Egberts, A.C.G. et al. What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research 19, 243 (2019). https://doi.org/10.1186/s12913-019-4065-6
dc.identifier.issn 1472-6963
dc.identifier.uri https://hdl.handle.net/20.500.11815/1764
dc.description Publisher's version (útgefin grein)
dc.description.abstract Background: Redispensing unused medications that have been returned to outpatient pharmacies by patients may reduce waste and healthcare costs. However, little is known regarding the extra costs associated with this process, nor the price level of medications for which this is economically beneficial. The objective of this study was to assess costs associated with redispensing unused medications in the pharmacy and the price level at which redispensing becomes cost-beneficial. Methods: A micro-costing study was conducted in four Dutch outpatient pharmacies for medications requiring room-temperature storage and requiring refrigeration. First, the pharmacy's necessary additional process steps and resources for redispensing were identified. Second, time required for each process step was simulated. Third, required resources were quantified by calculating labour, purchasing and overhead costs. Lastly, a model with different scenarios was constructed to calculate the price of a medication package at which redispensing becomes cost-beneficial. Results: Three main additional process steps for redispensing were identified: (1) pack medications with product quality indicators before dispensing, (2) assess quality of medications returned to the pharmacy (temperature storage, package integrity, expiry date) and (3a) restock medications fulfilling quality criteria or (3b) dispose of medications not fulfilling criteria. Total time required for all steps up to restock one medication package was on average 5.3 (SD ±0.3) and 6.8 (SD ±0.3) minutes for medications stored at room-temperature and under refrigeration, respectively, and associated costs were €5.54 and €7.61. Similar outcomes were found if a medication package would ultimately be disposed of. The price level primarily depended upon the proportion of dispensed packages returned unused to the pharmacy and fulfilling the quality criteria: if 5% is returned, of which 60% fulfils quality criteria, the price level was €101 per package for medications requiring room-temperature storage and €215 per package for those requiring refrigeration. However, if 10% is returned, of which 60% fulfils the quality criteria, the price level decreases to €53 and €109, respectively (arbitrary proportions). Conclusions: Redispensing unused medications in the pharmacy is at least cost-beneficial if applied to expensive medications.
dc.format.extent 243
dc.language.iso en
dc.publisher Springer Science and Business Media LLC
dc.relation.ispartofseries BMC Health Services Research;19(1)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Health Policy
dc.subject Cost-benefit ratio
dc.subject Healthcare economics
dc.subject Medication waste
dc.subject Micro-costing
dc.subject Redispensing
dc.subject Heilsuhagfræði
dc.subject Heilbrigðisstefna
dc.subject Lyfjaverslanir
dc.subject Lyf
dc.title What does it cost to redispense unused medications in the pharmacy? A micro-costing study
dc.type info:eu-repo/semantics/article
dcterms.license Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.description.version Peer Reviewed
dc.identifier.journal BMC Health Services Research
dc.identifier.doi 10.1186/s12913-019-4065-6
dc.contributor.department Lyfjafræðideild (HÍ)
dc.contributor.department Faculty of Pharmaceutical Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Skrár

Þetta verk birtist í eftirfarandi safni/söfnum:

Skoða venjulega færslu